查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1847858

利尿剂市场（按药物类别、适应症、给药途径、剂型和分销管道划分）－全球预测，2025-2032

Diuretics Drugs Market by Drug Class, Indication, Route Of Administration, Dosage Form, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年利尿剂市场将成长 25.4 亿美元，复合年增长率为 8.79%。

主要市场统计数据
基准年2024年 12.9亿美元
预计2025年 14.1亿美元
预测年份：2032年 25.4亿美元
复合年增长率（%） 8.79%

利尿剂的权威指导，整合临床效用、治疗多样性以及影响处方和获取的操作方面

利尿剂是各种临床环境中体液稳态管理的基石，其治疗效用涵盖从急性护理到慢性疾病管理的各个领域。临床医生使用不同类型的药物来达到精准的生理疗效，而处方管理者则权衡可互换药物和专利药物的疗效、安全性和成本。因此，利尿剂市场呈现出治疗需求、处方模式和供应链现实之间的复杂交互作用，这些因素会影响患者的用药管道和临床疗效。

过去十年，分子药理学、给药途径优化和联合用药策略的不断创新，改变了此类药物的处方思路，但并未改变其主要适应症。这种持久的相关性凸显了不仅要了解单一药物的药理学特性，还要了解监管变化、报销动态和不断变化的分销管道如何影响临床应用的重要性。因此，相关人员必须采取整体观点，将临床证据、营运限制和市场行为整合在一起。

本引言将作为后续分析的框架，该分析将综合考察影响策略决策的治疗应用转型、政策主导的贸易考量、细分市场主导的需求模式以及区域动态。本报告整合了临床、商业和监管分析，为企业主管和临床领导者提供整合的资源，帮助他们制定未来的优先事项、投资和产业计画。

临床精准度、现代分销、现实世界证据驱动的法规和供应链整合的变化如何重塑利尿策略

利尿剂领域正在经历一场变革，其驱动力在于不断变化的临床重点、供应链重组以及技术赋能的医疗模式。临床上，患者分层变得更加细緻，处方医师会根据患者的合併症、电解质风险和肾功能变化趋势，并客製化利尿剂的类别和药物。这种精准处方体现在，医生更注重减少不利事件，并管理多重用药族群的药物交互作用。

同时，供应链和分销管道正在适应不断变化的采购惯例和日益兴起的数位药局。医院和零售处方笺正在实施更严格的用药管理通讯协定，线上药局正在重新定义慢性病治疗的可近性。一些学名药领域的生产整合以及针对急性护理的注射剂和肠外给药的重点投资，加剧了这些转变。

此外，监管部门对药物安全检测和真实世界证据的重视程度不断提升，促使製造商投资于上市后安全项目和疗效研究。奖励价值和依从性的支付模式也影响相关人员的行为，鼓励器械和药物的共同开发，并提供病患支持服务，从而提高治疗的持久性。总而言之，这些变化代表着从以数量为导向的分销模式向以疗效主导的分销模式的转变，要求相关人员根据宏观经济和微观层面的压力重新调整其商业和临床战略。

评估2025年美国关税政策变化对筹资策略、製造地选择和采购弹性的结构性影响

美国于2025年实施的关税政策和国际贸易措施为医药原料和成品剂型的製造商、经销商和采购商带来了新的考量。关税表的变化影响了进口活性药物成分、某些辅料和专用包装组件的边际成本。因此，采购团队必须重新评估其供应商组合，多元化筹资策略，并优先与能够更好地抵御关税波动的供应商建立合作关係。

同时，进口关税的调整影响了某些製剂的境内外生产决策，尤其是在肠外和无菌注射剂生产线上，物流和法规合规性会造成巨大的营运摩擦。製造商重新评估了投资本地生产与全球采购弹性之间的权衡，并考虑了前置作业时间、品质保证以及无菌生产能力的资本密集度等因素。

对于医院系统和药局网路等下游买家而言，关税带来的成本压力促使他们重新谈判合约、优化库存，并重新专注于替代采购机制。集团采购组织和策略采购团队寻求更长期的供应协议和供应商管理的库存结构，以防范意外的成本上涨。总而言之，2025 年的关税变化引发了整个利尿剂价值链的结构性调整，加速了提高供应安全性和成本透明度的努力。

细粒度細項分析，将药物类别、临床适应症、给药方式、剂型和通路的细微差别与商业性和临床决策联繫起来

细分市场动态揭示了利尿剂亚类、临床适应症、给药途径、剂型和通路方面的需求驱动因素和差异。依药物类别划分，市场包括碳酸酐酶抑制剂、袢利尿剂、渗透性利尿剂、保钾利尿剂和噻嗪类利尿剂。在碳酸酐酶抑制剂中，Acetazolamide和多佐胺作用于不同的领域，包括眼部和全身；而袢利尿剂包括Bumetanide、依他尼酸、Furosemide和托拉塞米等药物，它们的效力、起效时间和肾臟处理方式各不相同。以甘露醇为代表的渗透性利尿剂主要用于急性颅内压和肾臟保护。保钾利尿剂，例如阿米洛利、依普利酮、Spiranolactone和氨苯蝶啶，是降低低血钾的治疗策略，但每种药物都有其独特的受体和代谢特征。噻嗪类利尿剂，例如芐氟噻嗪、Chlorthalidone和氢氯噻嗪，儘管半衰期和剂量存在差异，仍然是慢性高血压治疗的主要手段。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • SGLT2 抑制剂在心臟衰竭治疗的应用日益广泛，正在改变利尿剂的格局
  • 保钾利尿剂和抗高血压药物的固定剂量联合治疗的成长将推动市场创新
  • 盐皮质激素受体拮抗剂在难治性高血压治疗通讯协定的临床应用日益增多
  • 探险游客对预防高山症的口服Acetazolamide的需求激增
  • 扩大新型加压素受体拮抗剂治疗住院患者低钠血症的研究
  • 新兴的基于人工智慧和药物基因组学的个人化利尿剂剂量演算法，可改善肾臟预后

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 利尿剂市场（依药物类别）

  • 碳酸酐酶抑制剂
    • Acetazolamide
    • 多佐胺
  • 袢利尿剂
    • Bumetanide
    • 利尿酸
    • Furosemide
    • 托拉塞米
  • 渗透性利尿剂
    • 甘露醇
  • 保钾利尿剂
    • 阿米洛利
    • 依普立酮
    • Spiranolactone
    • 氨苯蝶啶
  • 噻嗪类利尿剂
    • 芐氟噻嗪
    • Chlorthalidone
    • 氢氯噻嗪

第九章 利尿剂市场（按适应症）

  • 浮肿
  • 青光眼
  • 心臟衰竭
  • 高血压
  • 肾臟疾病

第 10 章 利尿剂市场（依给药途径）

  • 口服
  • 肠外

第 11 章 利尿剂市场（以剂型）

  • 胶囊
  • 注射
  • 液体
  • 药片

第 12 章利尿剂市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第十三章 利尿剂市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 利尿剂市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 利尿剂市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Viatris Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma Limited
    • Dr. Reddy's Laboratories Limited
    • Hikma Pharmaceuticals PLC
    • Lupin Limited
    • Cipla Limited
    • Fresenius Kabi AG
Product Code: MRR-4103B31E0594

The Diuretics Drugs Market is projected to grow by USD 2.54 billion at a CAGR of 8.79% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.29 billion
Estimated Year [2025] USD 1.41 billion
Forecast Year [2032] USD 2.54 billion
CAGR (%) 8.79%

An authoritative orientation to diuretics that synthesizes clinical utility, therapeutic diversity, and the operational dimensions shaping prescribing and access

Diuretics remain foundational in the management of fluid homeostasis across multiple clinical contexts, and their therapeutic utility spans acute care settings to chronic disease management. Clinicians rely on diverse drug classes to achieve precise physiologic outcomes, while formulary managers weigh efficacy, safety, and cost across interchangeable and unique agents. As a result, the diuretics landscape presents a complex interplay between therapeutic need, prescribing patterns, and supply-chain realities that influence patient access and clinical outcomes.

Over the last decade, incremental innovations in molecular pharmacology, route-of-administration optimization, and fixed-dose combination strategies have altered prescribing rationales without displacing the class's core indications. This sustained relevance underscores the importance of understanding not only the pharmacologic profiles of individual agents, but also how regulatory shifts, reimbursement dynamics, and distribution channel evolution impact their clinical uptake. Consequently, stakeholders must adopt a holistic perspective that integrates clinical evidence, operational constraints, and market behaviors.

This introduction frames the subsequent analysis, which examines transformative shifts in therapy adoption, policy-driven trade considerations, segmentation-driven demand patterns, and regional dynamics that collectively shape strategic decision-making. By synthesizing clinical, commercial, and regulatory lenses, the report equips executives and clinical leaders with a cohesive narrative to inform prioritization, investment, and operational planning moving forward.

How shifting clinical precision, distribution modernization, regulatory emphasis on real-world evidence, and supply-chain consolidation are reshaping diuretics strategy

The diuretics arena is undergoing transformative shifts driven by evolving clinical priorities, supply-chain reorganization, and technology-enabled care models. Clinically, patient stratification has become more nuanced, with prescribers increasingly selecting diuretic class and agent to align with comorbidity profiles, electrolyte risk, and renal function trajectories. This precision in prescribing is mirrored by heightened attention to adverse event mitigation and drug-drug interaction management in polypharmacy populations.

Concurrently, supply-chain and distribution channels are adapting to changing procurement practices and the growing prominence of digital pharmacies. Hospital and retail formularies are implementing tighter utilization management protocols, while online pharmacies are redefining access pathways for chronic therapies. These shifts are compounded by manufacturing consolidation in certain generics segments and targeted investment in injectable and parenteral formulations for acute care settings.

Moreover, regulatory emphasis on pharmacovigilance and real-world evidence has intensified, prompting manufacturers to invest in post-marketing safety programs and outcome studies. Payment models that incentivize value and adherence have also influenced stakeholder behavior, encouraging device-drug co-development and patient-support services that enhance therapeutic persistence. Taken together, these changes represent a move from volume-driven distribution to outcome-oriented approaches, requiring stakeholders to recalibrate commercial and clinical strategies in response to both macroeconomic and micro-level pressures.

Evaluating the structural consequences of United States tariff policy changes in 2025 on sourcing strategies, manufacturing location choices, and procurement resilience

Tariff policy and international trade measures enacted in the United States in 2025 introduced new considerations for manufacturers, distributors, and purchasers of pharmaceutical ingredients and finished dosage forms. Changes in tariff schedules affected the marginal costs associated with imported active pharmaceutical ingredients, certain excipients, and specialized packaging components. As a result, procurement teams have had to re-evaluate supplier portfolios, diversify sourcing strategies, and prioritize supplier relationships that deliver resilience against tariff volatility.

At the same time, import-duty adjustments influenced decisions about onshoring versus offshore production for specific formulations, particularly for parenteral and sterile injectable lines where logistics and regulatory compliance present higher operational friction. Manufacturers re-assessed the trade-offs between localized production investment and the flexibility of global sourcing, considering lead-times, quality assurance regimes, and the capital intensity of sterile manufacturing capacity.

For downstream purchasers such as hospital systems and pharmacy networks, tariff-induced cost pressures prompted renewed focus on contract renegotiation, inventory optimization, and alternative procurement mechanisms. Group purchasing organizations and strategic sourcing teams explored longer-term supply agreements and vendor-managed inventory constructs to buffer against episodic cost increases. In sum, tariff changes in 2025 acted as a catalyst for structural adjustments across the diuretics value chain, accelerating initiatives that enhance supply stability and cost transparency.

Granular segmentation analysis that connects drug class nuances, clinical indications, administration modes, dosage formats, and distribution pathways to commercial and clinical decision-making

Segment-level dynamics reveal disparate drivers of demand and differentiation among diuretic subclasses, clinical indications, administration routes, dosage forms, and distribution channels. Based on drug class, the market encompasses carbonic anhydrase inhibitors, loop diuretics, osmotic diuretics, potassium-sparing diuretics, and thiazide diuretics; within carbonic anhydrase inhibitors, acetazolamide and dorzolamide serve distinct ocular and systemic niches, while loop diuretics include agents such as bumetanide, ethacrynic acid, furosemide, and torasemide that vary in potency, onset, and renal handling. Osmotic diuretics are represented by mannitol and are primarily utilized in acute intracranial pressure and renal protection scenarios. Potassium-sparing diuretics, including amiloride, eplerenone, spironolactone, and triamterene, offer therapeutic strategies to mitigate hypokalemia, with each agent carrying unique receptor and metabolic profiles. Thiazide diuretics such as bendroflumethiazide, chlorthalidone, and hydrochlorothiazide remain central to chronic hypertension management with differing half-lives and dosing considerations.

Based on indication, therapeutic use spans edema, glaucoma, heart failure, hypertension, and renal disease, each presenting distinct clinical endpoints, monitoring requirements, and reimbursement considerations. For example, agents targeting glaucoma emphasize topical tolerability and formulation stability, whereas heart failure and edema management prioritize diuretic efficacy, renal function monitoring, and interactions with guideline-directed medical therapies. Based on route of administration, the field divides into oral and parenteral strategies, with parenteral formulations playing a critical role in acute care settings where rapid natriuresis or intracranial pressure control is required.

Based on dosage form, stakeholders must reconcile differences among capsules, injectables, liquids, and tablets, as each form presents distinct manufacturing and supply-chain implications as well as patient adherence effects. Finally, based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways shape access, inventory practices, and clinician prescribing behaviors; hospital channels emphasize inpatient stocking and clinical protocols, online channels accelerate direct-to-patient continuity for chronic therapy, and retail channels remain central to community-based maintenance therapy. Integrating these segmentation lenses provides a granular framework for prioritizing development, commercialization, and operational investments across the product life cycle.

Regional dynamics and strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine access, manufacturing focus, and distribution tactics

Regional dynamics in diuretics consumption and strategic emphasis vary according to healthcare system structure, regulatory posture, and demographic needs. In the Americas, integrated hospital systems and expansive outpatient networks prioritize evidence-based formularies and therapeutic protocols for chronic disease management, with particular attention to hypertension and heart failure pathways. This region's distribution channels include robust retail pharmacy penetration alongside growing digital pharmacy adoption, which together influence prescribing continuity and access to generics and branded formulations.

Europe, the Middle East & Africa exhibit heterogeneous patterns driven by varying regulatory harmonization, reimbursement architectures, and infrastructure capacity. In many European healthcare systems, centralized procurement and stringent pharmacoeconomic assessment shape adoption patterns while pockets of private-sector innovation and specialty care expand access to advanced formulations. The Middle East and Africa demonstrate a wide range of access challenges and growth opportunities, with some markets emphasizing local manufacturing capability building and others prioritizing expanded distribution networks to reach underserved populations. Cross-regional collaboration and supply security remain central to stakeholders operating across these territories.

Asia-Pacific is characterized by a diverse mix of high-capacity healthcare markets alongside emerging economies where demographic trends and rising chronic disease prevalence increase long-term demand for diuretics. This region shows active investment in both generic manufacturing scale-up and in tailored patient support programs that address adherence and affordability. Trade policies, regional manufacturing clusters, and evolving regulatory frameworks further influence how manufacturers and distributors deploy resources across product portfolios. Collectively, these regional insights underscore the need for adaptive commercial models that align product strategy with local clinical priorities and logistical realities.

Competitive dynamics centered on manufacturing excellence, formulation differentiation, strategic partnerships, and evidence generation that define leadership in diuretics

Key competitive dynamics reflect a convergence of generic competition, targeted product differentiation, and strategic partnerships that span clinical development to distribution. Within the diuretics therapeutic area, established generic manufacturers maintain a strong presence due to long-standing agents with well-characterized profiles, while specialized pharmaceutical companies differentiate through formulation innovation, injectable capacity, and therapeutic support services. Partnerships between manufacturers and health systems or specialty pharmacies increasingly prioritize adherence programs and integrated care pathways that demonstrate measurable outcomes.

Intellectual property considerations are less dominant for older small-molecule diuretics, which elevates the importance of manufacturing quality, supply reliability, and commercial execution. Consequently, companies that can combine robust manufacturing compliance, a diversified product portfolio across drug classes, and flexible distribution arrangements typically achieve competitive advantage. In addition, strategic alliances that secure raw material supply, co-develop novel delivery systems, or expand geographic market access are central to sustaining revenue streams in a crowded generics environment.

Finally, investment in pharmacovigilance and real-world evidence generation serves as a differentiator for companies seeking to position legacy therapies within outcome-focused care models. Firms that can present credible safety and adherence data, alongside support tools that facilitate clinician decision-making, will be better positioned to influence formulary decisions and institutional procurement policies.

Operational and commercial playbook recommendations that align supply resilience, formulation differentiation, evidence generation, and channel-specific go-to-market execution

Industry leaders should adopt an integrated strategy that aligns clinical utility with operational resilience and commercial differentiation. First, prioritize supply-chain diversification and contingency planning that reduce exposure to tariff-related cost shifts and single-source dependencies. Investment in dual-sourcing arrangements, regional manufacturing partnerships, and vendor-managed inventory options can materially improve supply continuity and mitigate pricing volatility.

Second, elevate product differentiation through formulation and service enhancements that respond to clinical use cases. For ocular indications, emphasize tolerability and preservative-free formulations. For heart failure and edema, develop patient-support solutions that assist monitoring and adherence, and consider collaborations with digital health platforms to integrate medication reminders and outcome tracking. These initiatives should be supported by targeted real-world evidence generation to demonstrate value to payers and institutional buyers.

Third, refine go-to-market approaches across distribution channels by tailoring pricing, packaging, and educational assets to hospital, online, and retail pharmacy stakeholders. Engage early with hospital formulary committees and clinical champions to align on protocol adoption, and deploy commercial models that account for the unique procurement cycles of each channel. Finally, maintain a forward-looking regulatory and policy scanning capability to anticipate trade or reimbursement shifts, enabling proactive adjustments to sourcing and commercialization plans. Together, these actions will strengthen market positioning while supporting long-term patient access and clinical outcomes.

Robust multi-source research methodology combining stakeholder interviews, clinical literature synthesis, segmentation mapping, and scenario analysis for verified insights

This research synthesizes multiple evidence streams to construct a comprehensive understanding of the diuretics landscape. Primary qualitative inputs included interviews with clinical specialists, hospital pharmacy directors, procurement leaders, and commercial executives to capture real-world decision criteria and operational constraints. Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, and public-domain product labeling to ensure pharmacologic accuracy and clinical relevance.

Analytical methods incorporated cross-segmentation mapping to link drug-class characteristics with indication-specific requirements, route-of-administration implications, dosage-form manufacturing considerations, and distribution-channel behaviors. Regional analysis drew on policy reviews, trade data patterns, and healthcare system profiles to explain divergent access and manufacturing priorities. Scenario analysis examined the operational impact of trade-policy shifts and supply-disruption events to inform actionable recommendations.

Quality assurance for the research included data triangulation across independent sources, validation of clinical assertions with practicing clinicians, and methodological peer review to ensure analytical rigor. Where applicable, the study prioritized transparency in assumptions and clearly delineated inference from empiric evidence so decision-makers can assess applicability to their specific context.

A final synthesis emphasizing the enduring clinical importance of diuretics and the strategic actions needed to convert intelligence into sustained operational and commercial advantage

In closing, the diuretics therapeutic area continues to be pivotal across a spectrum of clinical conditions, with enduring relevance driven by both foundational agents and incremental innovations. The landscape is simultaneously stable in its clinical utility and dynamic in its commercial and operational contours, influenced by shifting prescribing practices, distribution modernization, and policy developments. Stakeholders that appreciate both the pharmacologic subtleties of individual agents and the macro-level forces shaping access will be best positioned to make informed strategic choices.

Future competitiveness will hinge on the ability to integrate supply resilience with patient-centric product and service offerings, underpinned by credible evidence that translates into payer and provider confidence. By aligning manufacturing excellence, differentiated formulation strategies, and targeted commercial execution across regional contexts, organizations can preserve therapeutic value while adapting to evolving healthcare demands. Ultimately, proactive strategy and operational discipline will determine which organizations convert market intelligence into durable clinical and commercial advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of SGLT2 inhibitors in heart failure management transforming diuretics landscape
  • 5.2. Growth in fixed-dose combination therapies integrating potassium-sparing diuretics with antihypertensives driving market innovation
  • 5.3. Increasing clinical use of mineralocorticoid receptor antagonists in resistant hypertension treatment protocols
  • 5.4. Surge in demand for oral acetazolamide formulations in altitude sickness prevention among adventure tourism participants
  • 5.5. Expansion of research into novel vasopressin receptor antagonists for hyponatremia management in hospitalized patients
  • 5.6. Emergence of personalized diuretic dosing algorithms leveraging AI and pharmacogenomics for improved renal outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diuretics Drugs Market, by Drug Class

  • 8.1. Carbonic Anhydrase Inhibitors
    • 8.1.1. Acetazolamide
    • 8.1.2. Dorzolamide
  • 8.2. Loop Diuretics
    • 8.2.1. Bumetanide
    • 8.2.2. Ethacrynic Acid
    • 8.2.3. Furosemide
    • 8.2.4. Torasemide
  • 8.3. Osmotic Diuretics
    • 8.3.1. Mannitol
  • 8.4. Potassium-Sparing Diuretics
    • 8.4.1. Amiloride
    • 8.4.2. Eplerenone
    • 8.4.3. Spironolactone
    • 8.4.4. Triamterene
  • 8.5. Thiazide Diuretics
    • 8.5.1. Bendroflumethiazide
    • 8.5.2. Chlorthalidone
    • 8.5.3. Hydrochlorothiazide

9. Diuretics Drugs Market, by Indication

  • 9.1. Edema
  • 9.2. Glaucoma
  • 9.3. Heart Failure
  • 9.4. Hypertension
  • 9.5. Renal Disease

10. Diuretics Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Diuretics Drugs Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Injectable
  • 11.3. Liquid
  • 11.4. Tablet

12. Diuretics Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Diuretics Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Diuretics Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Diuretics Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Teva Pharmaceutical Industries Ltd.
    • 16.3.2. Sandoz International GmbH
    • 16.3.3. Viatris Inc.
    • 16.3.4. Sun Pharmaceutical Industries Ltd.
    • 16.3.5. Aurobindo Pharma Limited
    • 16.3.6. Dr. Reddy's Laboratories Limited
    • 16.3.7. Hikma Pharmaceuticals PLC
    • 16.3.8. Lupin Limited
    • 16.3.9. Cipla Limited
    • 16.3.10. Fresenius Kabi AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIURETICS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIURETICS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DIURETICS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DIURETICS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DIURETICS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DIURETICS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIURETICS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIURETICS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIURETICS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DORZOLAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DORZOLAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DORZOLAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DORZOLAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DORZOLAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DORZOLAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BUMETANIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BUMETANIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BUMETANIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BUMETANIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BUMETANIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BUMETANIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ETHACRYNIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ETHACRYNIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ETHACRYNIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ETHACRYNIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ETHACRYNIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ETHACRYNIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIURETICS DRUGS MARKET SIZE, BY FUROSEMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIURETICS DRUGS MARKET SIZE, BY FUROSEMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIURETICS DRUGS MARKET SIZE, BY FUROSEMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIURETICS DRUGS MARKET SIZE, BY FUROSEMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIURETICS DRUGS MARKET SIZE, BY FUROSEMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIURETICS DRUGS MARKET SIZE, BY FUROSEMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TORASEMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TORASEMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TORASEMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TORASEMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TORASEMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TORASEMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIURETICS DRUGS MARKET SIZE, BY MANNITOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIURETICS DRUGS MARKET SIZE, BY MANNITOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIURETICS DRUGS MARKET SIZE, BY MANNITOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIURETICS DRUGS MARKET SIZE, BY MANNITOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIURETICS DRUGS MARKET SIZE, BY MANNITOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIURETICS DRUGS MARKET SIZE, BY MANNITOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIURETICS DRUGS MARKET SIZE, BY AMILORIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIURETICS DRUGS MARKET SIZE, BY AMILORIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIURETICS DRUGS MARKET SIZE, BY AMILORIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIURETICS DRUGS MARKET SIZE, BY AMILORIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIURETICS DRUGS MARKET SIZE, BY AMILORIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIURETICS DRUGS MARKET SIZE, BY AMILORIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EPLERENONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EPLERENONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EPLERENONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EPLERENONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EPLERENONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EPLERENONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIURETICS DRUGS MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DIURETICS DRUGS MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIURETICS DRUGS MARKET SIZE, BY SPIRONOLACTONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DIURETICS DRUGS MARKET SIZE, BY SPIRONOLACTONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIURETICS DRUGS MARKET SIZE, BY SPIRONOLACTONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DIURETICS DRUGS MARKET SIZE, BY SPIRONOLACTONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TRIAMTERENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TRIAMTERENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TRIAMTERENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TRIAMTERENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TRIAMTERENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TRIAMTERENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BENDROFLUMETHIAZIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BENDROFLUMETHIAZIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BENDROFLUMETHIAZIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BENDROFLUMETHIAZIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BENDROFLUMETHIAZIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BENDROFLUMETHIAZIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CHLORTHALIDONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CHLORTHALIDONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CHLORTHALIDONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CHLORTHALIDONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CHLORTHALIDONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CHLORTHALIDONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EDEMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EDEMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EDEMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EDEMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EDEMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EDEMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIURETICS DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DIURETICS DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIURETICS DRUGS MARKET SIZE, BY GLAUCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DIURETICS DRUGS MARKET SIZE, BY GLAUCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIURETICS DRUGS MARKET SIZE, BY GLAUCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DIURETICS DRUGS MARKET SIZE, BY GLAUCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RENAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RENAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RENAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RENAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RENAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RENAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DIURETICS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DIURETICS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DIURETICS DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DIURETICS DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DIURETICS DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DIURETICS DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DIURETICS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DIURETICS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS DIURETICS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS DIURETICS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE DIURETICS DRUGS MARKET SIZE, BY